DDInter466 DDInter1376
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dactinomycin {u} (Compound) treats {v} (Disease) germ cell cancer
Dactinomycin {u} (Compound) binds {v} (Gene) ABCB1
Dactinomycin {u} (Compound) upregulates {v} (Gene) PRR15L
Dactinomycin {u} (Compound) downregulates {v} (Gene) RNPS1
Dactinomycin {u} (Compound) causes {v} (Side Effect) Discomfort
Dactinomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Dactinomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Dactinomycin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Dactinomycin (Compound) treats germ cell cancer (Disease)
Dactinomycin (Compound) binds ABCB1 (Gene)
Dactinomycin (Compound) upregulates PRR15L (Gene)
Dactinomycin (Compound) downregulates RNPS1 (Gene)
Dactinomycin (Compound) causes Discomfort (Side Effect)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Dactinomycin may lead to a major life threatening interaction when taken with Leflunomide